Cagrilintide
An investigational amylin analog being studied in clinical trials; not FDA-approved.
What it is
Cagrilintide is a long-acting analog of amylin — a hormone co-secreted with insulin that promotes satiety. It is an investigational drug, best known as the partner in 'CagriSema,' a combination with semaglutide in late-stage trials.
Phase 2 and 3 data show substantial average weight reductions for the combination, which is why the name escaped the trial world and appeared on gray-market sites. No approval exists yet anywhere, and the trial evidence belongs to pharmaceutical products under monitoring, not to vials sold online.
What researchers have actually studied it for
Obesity, alone and combined with semaglutide (CagriSema), in ongoing late-stage clinical trials; not yet approved anywhere.
How it works
Amylin is the pancreas's second satiety messenger, released alongside insulin. Cagrilintide mimics it with engineering for week-long action, working satiety circuits in the hindbrain that partially differ from GLP-1's hypothalamic pathways — the complementarity that motivates combining the two.
The molecule itself
A long-acting analog of amylin — the 37-amino-acid hormone co-secreted with insulin — stabilized against the aggregation that makes natural amylin notoriously difficult chemistry (amylin aggregates are the stuff of pancreatic amyloid). Lipidation provides the weekly-action albumin anchor.
Where it came from
Amylin pharmacology has one approved ancestor — pramlintide, a short-acting analog used with insulin since 2005. Novo Nordisk's long-acting cagrilintide revived the pathway for obesity, alone and in the CagriSema combination that reached phase 3 with headline average reductions in the low-to-mid 20% range.
The timeline
2005
Pramlintide, the short-acting amylin analog, approved — the pathway's proof of concept.
2021
Cagrilintide phase 2 shows meaningful monotherapy weight loss.
2024–25
REDEFINE phase 3 program reports large average reductions for the CagriSema combination.
What the research record actually contains
- Phase 2 monotherapy trials: dose-dependent weight reduction as a single agent.
- REDEFINE program (CagriSema): phase 3 combination trials reporting large average weight reductions.
- No approval, no label, and long-term safety characterization still in progress.
What could change this assessment
Approval decisions on CagriSema are the watch item; results to date position it as the GLP-1 era's first major combination franchise. Amylin-only programs (cagrilintide solo and successors) are also advancing for patients who tolerate incretins poorly.
What's known about risks
GI effects dominate reported data, consistent with satiety-pathway drugs. As an investigational compound, its safety file is by definition incomplete — and the combination's long-term profile is exactly what the ongoing program is for.
Where it stands legally
Unapproved everywhere; no lawful consumer channel exists. Online 'cagrilintide' is an unregulated research chemical trading on trial headlines.
Worth asking a licensed provider
- 1.Do approved options already cover what I'd be hoping CagriSema delivers?
- 2.Is trial enrollment a realistic path for me?
- 3.What in my history would make an amylin-pathway drug attractive or inappropriate?
Common claims, corrected
“CagriSema is available if you know where to look.”
Reality: No approval exists anywhere; anything sold under the name is unregulated chemistry trading on trial headlines.
“Amylin drugs are just GLP-1 drugs by another name.”
Reality: Different hormone, partially different brain circuits — the combination exists precisely because the signals complement rather than duplicate.
Cagrilintide FAQ
What is CagriSema?
A fixed combination of cagrilintide and semaglutide in late-stage trials — amylin and GLP-1 signaling together. Trial results show large average weight reductions; approval decisions are still ahead.
Is cagrilintide available now?
Not lawfully — it has no approval anywhere. Online 'cagrilintide' is an unregulated research chemical trading on trial headlines.
How does amylin signaling differ from GLP-1?
Amylin acts on satiety circuits partly distinct from GLP-1's, which is the rationale for combining them: two complementary appetite signals rather than a doubled dose of one.
What is amylin's natural job?
Co-released with insulin, it slows gastric emptying and signals satiety through hindbrain circuits — the meal-ending hormone to insulin's storage hormone.
Why combine it with semaglutide?
Two complementary satiety pathways beat doubling one: trials of the combination report average reductions beyond either component's ceiling.